A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial-intelligence-powered analysis to provide what the company says could become ...

Delta-like ligand 3 (DLL3) is a highly relevant target for radiopharmaceutical therapy due to its expression in more than 85% of tumors of patients with small-cell lung cancer.

Researchers have identified a single protein whose absence can cripple tumors in mice, slowing their growth and in some cases ...

Proteins that are no longer needed, defective, or potentially harmful are labeled with a molecular "tag" and dismantled in ...

Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection rates continue to rise.

Researchers at the University of Southampton have developed a promising new way to bolster the body's immune system response to cancer.